Vertex Stock Falls 4.8% in a Month: Buying Opportunity or Red Flag?

VRTX stock slips nearly 5% as concerns over new drug uptake and pipeline setbacks weigh, even as its dominant CF franchise continues to drive steady growth.

Zacks Investment Research • 13 minutes ago

My Top 3 Drug Stocks for March 2026

Innovative drugmakers tend to perform well over the long run. These three drug stocks can launch new products while maintaining or improving their financial results.

The Motley Fool • 3 hours ago

Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals

Eli Lilly has strong momentum thanks to its leadership in the weight loss market. Vertex Pharmaceuticals' core franchise and newer approvals could drive top-line growth for a long time.

The Motley Fool • 19 hours ago

Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $451.59, denoting a -2.36% move from the preceding trading day.

Zacks Investment Research • Mar 18, 2026

TrumpRx lists many medicines at prices higher than paid in UK

U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those paid in the United Kingdom, ​according to a Reuters comparison of publicly available prices.

Reuters • Mar 18, 2026

Is Vertex Pharmaceuticals Heading to $600?

The biotech company is the leader in the cystic fibrosis market and is quickly expanding into other treatment areas. Vertex forecasts its newer medicines may add $500 million to revenue this year.

The Motley Fool • Mar 16, 2026

This Stock Just Jumped By 8%: Is It Too Late to Buy?

One of Vertex Pharmaceuticals' leading pipeline candidates just aced a phase 3 study. It could become an important growth driver while helping the biotech diversify its lineup.

The Motley Fool • Mar 13, 2026

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Investment Research • Mar 13, 2026

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Seeking Alpha • Mar 11, 2026

Vertex (VRTX) Moves 8.3% Higher: Will This Strength Last?

Vertex (VRTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research • Mar 11, 2026